e-Therapeutics employs advanced computational technologies to revolutionize drug discovery, particularly through its proprietary platforms, HepNet™ and GalOmic™. The HepNet™ platform focuses on hepatocyte-specific computational biology, utilizing extensive data sources and AI to identify novel gene targets and enhance drug design. This platform integrates a vast knowledge base, including over 14 million hepatocyte-specific data points, to drive the discovery of RNA interference (RNAi) therapies. By leveraging network analytics and AI, e-Therapeutics can efficiently assess potential drug targets, ensuring a robust pipeline of innovative therapeutic candidates.

The GalOmic™ platform complements HepNet™ by generating potent and safe GalNAc-siRNA therapeutics, which selectively silence disease-associated genes in hepatocytes. This targeted approach addresses significant unmet medical needs across various therapeutic areas, including metabolic dysfunction-associated steatohepatitis (MASH) and age-related macular degeneration (AMD). By streamlining the drug design process and enhancing the efficiency of therapeutic development, e-Therapeutics aims to accelerate the transition from discovery to clinical application, ultimately improving patient outcomes through the development of life-transforming RNAi medicines.

United Kingdom

A specialist in computational drug discovery with a focus on developing RNA interference (“RNAi”) therapeutics

e-Therapeutics

Company Details